Olanzapine intranasal - Neurelis
Alternative Names: NRL-1004; NRL-4Latest Information Update: 03 Dec 2024
At a glance
- Originator Neurelis
- Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Piperazines; Small molecules; Thiophenes
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Agitation
Most Recent Events
- 03 Dec 2024 Chemical structure information added.
- 01 Nov 2023 Neurelis completes a phase-I trials in Agitation (Intranasal, IM)(Neurelis pipeline, February 2024) (NCT06600477)
- 16 Oct 2023 Phase-I clinical trials in Agitation (Intranasal) in Jordan (Neurelis pipeline, February 2024) (NCT06600477)